<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2030">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04359706</url>
  </required_header>
  <id_info>
    <org_study_id>2020_28</org_study_id>
    <secondary_id>2020-A01042-37</secondary_id>
    <nct_id>NCT04359706</nct_id>
  </id_info>
  <brief_title>Bacterial and Fungal Microbiota of Patients With Severe Viral Pneumonia With COVID-19</brief_title>
  <acronym>MICROVID</acronym>
  <official_title>Bacterial and Fungal Microbiota of Patients With Severe Viral Pneumonia With SARS-CoV2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Lille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Observational pilot single-center study aiming to determine the microbiota of critically ill
      patients infected with SARS-CoV-2. COVID-19 patients will be compared to historical
      critically ill controls with no SARS-CoV-2 infection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Observational pilot single-center study aiming to determine the microbiota of critically ill
      patients infected with SARS-CoV-2. COVID-19 patients will be compared to historical
      critically ill controls with no SARS-CoV-2 infection.

      Respiratory and fecal microbiota (microbial and fungal) will be determined in COVID-19
      patients on bronchoalveolar lavage and rectal swab.

      Inflammatory biomarkers will also be measured in COVID-19 patients.

      Characteristics of study patients will be collected at ICU admission and during ICU stay.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 8, 2020</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Composition of the fecal bacterial and fungal microbiota</measure>
    <time_frame>At 28 days</time_frame>
    <description>relative abundances and diversity indices</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Analysis of the faecal microbiota from rectal swab</measure>
    <time_frame>at baseline and every 7 days during 28 days</time_frame>
    <description>Alterations in fecal microbiota composition (including virose, bacteria and fungi) in COVID-19 patients compared with controls</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of the respiratory microbiota from the bronchoalveolar lavage liquid</measure>
    <time_frame>at baseline and every 7 days during 28 days</time_frame>
    <description>Alterations in respiratory microbiota composition (including virose, bacteria and fungi) in COVID-19 patients compared with controls</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum inflammatory markers changes</measure>
    <time_frame>at 28 days,</time_frame>
    <description>Changes in blood, c-reactive protein, leucocyte, lymphocyte from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory markers changes</measure>
    <time_frame>at 28 days,</time_frame>
    <description>changes in Cytokine/ chemokine from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>at 28 days,</time_frame>
    <description>death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mechanical ventilation free days</measure>
    <time_frame>at 28 days,</time_frame>
    <description>Number of days alive without mechanical ventilation</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Sars-CoV2</condition>
  <arm_group>
    <arm_group_label>Covid-19 group</arm_group_label>
    <description>Critically ill patients with SARS-CoV-2 infection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <description>Historical critically ill patients with no SARS-CoV-2 infection</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      bronchoalveolar lavage and rectal swabs
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        patients suspected of SARS-CoV2 infection and admitted in ICU
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        For the Covid-19 Group: with a confirmed severe lung infection with CoV2-SARS-Cov2 admitted
        to the ICU.

        For the Control Group:

          -  Historic cohort of non SARS -CoV2-infected adults admitted to the ICU (between March
             and October 2019),

          -  that was investigated for fecal microbiota in a previous study (control patients in a
             fecal microbiota study in patients included in the SEAT study).

        Exclusion Criteria:

          -  For the Covid-19 group:

          -  Lack of coverage Patients who received antibiotic therapy within 6 weeks prior to
             Covid-19 symptomatology,

          -  Pregnant women,

          -  Severe immunosuppression: Neutropenia &lt; 0.5 G/L, Chemotherapy &lt; 6 months, Bone marrow
             transplant recipients, HIV with CD4+ lymphocytes &lt; 0.4 G/L

          -  Impossible to perform bronchoalveolar lavage,

          -  Non-socially insured,

          -  Refusal to participate in the social study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Saad Nseir, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Lille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Saad Nseir, MD,PhD</last_name>
    <phone>0320445962</phone>
    <phone_ext>+33</phone_ext>
    <email>saadalla.nseir@chru-lille.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>HÃ´pital Roger Salengro, CHU Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>0320445962</phone>
    </contact>
    <investigator>
      <last_name>Saadalla NSEIR, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 21, 2020</study_first_submitted>
  <study_first_submitted_qc>April 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2020</study_first_posted>
  <last_update_submitted>August 4, 2020</last_update_submitted>
  <last_update_submitted_qc>August 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia, Viral</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

